Myocardial infarction in the elderly

Aging and Disease

Volumn 2, Issue 2, 2011, Pages 116-137

  Carro, Amelia ^a   Kaski, Juan Carlos ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acute myocardial infarction; Age; Management of elderly patients; Myocardial reperfusion

Indexed keywords

EID: 84856086324     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Murray CJ, Lopez AD (1997). Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 349:1269-1276.
2. Mathers CD, Bernard C, Iburg KM, Inoue M, Ma Fat D, Shibuya K, et al. Global burden of disease in 2002: data sources, methods and results. Geneva: World Health Organization; 2003 (GPE Discussion Paper No. 54)
3. The future of CVD. In: Mackay J, Mensah G, eds. The Atlas of Heart Disease and Stroke. Geneva, Switzerland: World Health Organization; 2004:74-75. Available at: http://www.who.int/cardiovascular _diseases/en/cvd_atlas_25_future.pdf. Accessed October 18, 2010.
4. Sugiura M, Hiraoka K, Ohkawa S (1976). Severity of coronary sclerosis in the aged: a pathological study in 968 consecutive autopsy cases. Jpn Heart J;17:471-478
5. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, et al. (1999). Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol., 19(3):538-545.
6. Kuller L, Borhani N, Furberg C, Gardin J, Manolio T, O'Leary D, et al. (1994). Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol., 139(12):1164-1179.
7. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998). Prediction of coronary heart disease using risk factor categories. Circulation., 97(18):1837-1847
8. GRACE Investigators (2001). Rationale and design of the GRACE (Global Registry of Acute Coronary Events) project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J, 141:190-199.
9. Alexander KP, Roe MT, Chen AY, Lytle BL, Pollack CV Jr, Foody JM, et al. (2005). Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol, 46:1479-1487.
10. Gurwitz JH, Col NF, Avorn J (1992). The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA, 268(11):1417-1422.
11. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C (1999). Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy, 4:112-121
12. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, et al; GUSTO-I Investigators (1995). Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation, 91:1659-1668.
13. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED (2001). Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA, 286:708-713
14. Krumholz HM, Gross CP, Peterson ED, Barron HV, Radford MJ, Parsons LS, et al. (2003). Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 Study. Am Heart J, 146:839-847.
15. Melgarejo-Moreno A, Galcera-Tomas J, Garcia-Alberola A, Rodriguez-Garcia P, Gonzalez-Sanchez A (1999). Clinical and prognostic characteristics associated with age and gender in acute myocardial infarction: a multihospital perspective in the Murcia region of Spain. Eur J Epidemiol, 15:621-9
16. Rittger H, et al. (2009). Influence of age on pain perception in acute myocardial ischemia: A possible cause for delayed treatment in elderly patients. Int J Cardiol, doi:10.1016/j.ijcard.2009.11.046
17. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, et al. (1994) Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation, 90(4):2103-14
18. Milner KA, Vaccarino V, Arnold AL, Funk M, Goldberg RJ (2004). Gender and age differences in chief complaints of acute myocardial infarction (Worcester Heart Attack Study). Am J Cardiol, 93:606-608
19. Aronow WS (1987). Prevalence of presenting symptoms of recognized acute myocardial infarction and of unrecognized healed myocardial infarction in elderly patients. Am J Cardiol, 60:1182
20. Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz DA, et al. (2000). Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol, 36(7):2056-63
21. Sgarbossa EB, Wagner G (2007). Electrocardiography. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. 3 rd ed. Philadelphia: Lippincott-Raven, 978-1011
22. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction (2007). Universal definition of myocardial infarction. Eur Heart J, 28(20):2525-38
23. Jeremias A, Gibson M (2005). Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med, 142:786-791.
24. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, et al. Val-HeFT Investigators (2007). Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation, 116:1242-1249.
25. Schulz O, Paul-Walter C, Lehmann M, Abraham K, Berghöfer G, Schimke I, et al. (2007). Usefulness of detectable levels of troponin, below the 99th percentile of the normal range, as a clue to the presence of underlying coronary artery disease. Am J Cardiol, 100: 764-769.
26. Zethelius B, Johnston N, Venge P (2006). Troponin I as a predictor of coronary heart disease and death in 70-year old apparently healthy men. Circulation, 113:1071-1078.
27. Eggers KM, Lind L, Ahlström H, Bjerner T, Ebeling Barbier C, Larsson A, et al. (2008). Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J, 29:2252-2258.
28. Eggers KM, Lind L, Venge P, Lindahl B. (2009) Will the universal definition of myocardial infarction criteria result in an overdiagnosis of myocardial infarction? Am J Cardiol.;103(5):588-91.
29. Inbar R, Shoenfeld Y (2009). Elevated cardiac troponins: the ultimate marker for myocardial necrosis, but not without a differential diagnosis. Isr Med Assoc J, 11(1):50-3.
30. Yarzebski J, Goldberg RJ, Gore JM, Alpert JS (1994). Temporal trends and factors associated with extent of delay to hospital arrival in patients with acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J, 128:255-263
31. Goldberg RJ, Yarzebski J, Lessard D, Gore JM (2000). Decade-long trends and factors associated with time to hospital presentation in patients with acute myocardial infarction: the Worcester Heart Attack Study. Arch Intern Med, 160:3217-3223
32. Gurwitz JH, McLaughlin TJ, Willison DJ, Guadagnoli E, Hauptman PJ, Gao X, etal. (1997). Delayed hospital presentation in patients who have had acute myocardial infarction. Ann Intern Med, 126: 593-599.
33. Avezum A, Makdisse M, Spencer F, Gore JM, Fox KA, Montalescot G, et al. (2005). Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J, 149:67-73
34. Goldberg RJ, Steg PG, Sadiq I, Granger CB, Jackson EA, Budaj A, et al. (2002). Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (The GRACE Registry). Am J Cardiol, 89:791-796.
35. Saczynski JS, Yarzebski J, Lessard D, Spencer FA, Gurwitz JH, Gore JM, et al. (2008). Trends in prehospital delay in patients with acute myocardial infarction (from the Worcester Heart Attack Study). Am J Cardiol 102(12):1589-1594.
36. Ottesen MM, Kober L, Jorgensen S, Torp-Pedersen C (1996). Determinants of delay between symptoms and hospital admission in 5978 patients with acute myocardial infarction. The TRACE Study Group. Trandolapril Cardiac Evaluation. Eur Heart J, 17:429-437.
37. White HD, Barbash GI, CaliffRM, Simes RJ, Granger CB, Weaver WD, et al. (1996). Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. Circulation, 94: 1826-1833.
38. Newby LK, Rutsch WR, CaliffRM, Simoons ML, Aylward PE, Armstrong PW, et al; GUSTO-1 Investigators (1996). Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol, 27:1646-1655
39. Van De Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al; ESC Committee for Practice Guidelines (CPG) (2008). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 29(23):2909-45.
40. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. (2004). ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol, 44:671-719.
41. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. (2009). 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 54(23):2205-41.
42. The GUSTO Investigators (1993). An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med, 329:673-682.
43. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators (1997). A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med, 336:1621-1628.
44. Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, et al; Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators (1998). TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation, 98: 2805-2814.
45. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators; Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, et al (1999). Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet, 354:716-722.
46. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators (2001). Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet, 358:605-613.
47. Topol EJ; GUSTO V Investigators (2001). Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet, 357:1905-1914.
48. White H; Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators (2001). Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet, 358:1855-1863.
49. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, et al. (2003). Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction. Circulation, 108:135-142.
50. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al; the Primary Angioplasty in Myocardial Infarction Study Group (1993). A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med, 328:673-679.
51. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H (1993). A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med, 328: 680-684.
52. Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, et al. (1999). Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med, 341:1413-1419.
53. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al; DANAMI-2 Investigators (2003). A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med, 349:733-742.
54. Goldenberg I, Matetzky S, Halkin A, Roth A, Di Segni E, Freimark D, et al. (2003). Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction. Am Heart J, 145:862-867.
55. Keeley EC, Boura JA, Grines CL (2003). Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet, 361:13-20.
56. Mehta RH, Granger CB, Alexander KP, Bossone E, White HD, Sketch H Jr (2005). Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks. J Am Coll Cardiol, 45:471-478.
57. Thiemann DR, Coresh J, Oetgen WH, Powe NR (1999). The association between hospital and survival after acute myocardial infarction in elderly patients. N Engl J Med, 340:1640-1648.
58. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez- Sendon J; GRACE Investigators (2002). Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet, 359:373-377.
59. Krumholz HM, Friesinger GC, Cook EF, Lee TH, Rouan GW, Goldman L (1994). Relationship of age with eligibility for thrombolytic therapy and mortality among patients with suspected acute myocardial infarction. J Am Geriatr Soc, 42:127-131.
60. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group (1994). Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet, 343:311-322.
61. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, 2:349-360
62. Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (1990). GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet, 336:65-71.
63. Third International Study of Infarct Survival. Collaborative Group (1992). ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet, 339:753-770.
64. CaliffRM, Topol EJ, George BS, Boswick JM, Abbottsmith C, Sigmon KN, et al. (1988). Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med, 85:354-359.
65. Anderson JL, Karagounis L, Allen A, Bradford MJ, Menlove RL, Pryor TA (1991). Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol, 68:166-170.
66. De Jaegere PP, Arnold AA, Balk AH, Simoons ML (1992). Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. J Am Coll Cardiol, 19:289-294.
67. Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G (1992). The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med, 327:1-6.
68. Lesnefsky EJ, Lundergan CF, Hodgson JM, Nair R, Reiner JS, Greenhouse SW, et al. (1996). Increased left ventricular dysfunction in elderly patients despite succesful thrombolysis: the GUSTO-1 angiographic experience. J Am Coll Cardiol, 28: 331-337.
69. White H (2000). Thrombolytic therapy in the elderly: weighing up the risks and benefits. Lancet, 356:2028-30.
70. Stenestrand U, Wallentin L; Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RISK-HIA) (2003). Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction. One-year follow-up of a large prospective cohort. Arch Intern Med, 163:965-971.
71. Berger AK, Radford MJ, Wang Y, Krumholz HM (2000). Thrombolytic therapy in older patients. J Am Coll Cardiol, 36(2):366-74.
72. Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, Powe NR (2000). Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation, 101(19):2239-46.
73. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Christiansen CL, Gurwitz JH (2002). Effectiveness of thrombolytic therapy for acute myocardial infarction in the elderly: cause for concern in the old-old. Arch Intern Med, 162(5):561-568.
74. Brass LM, Lichtman JH, Wang Y, Gurwitz JH, Radford MJ, Krumholz HM (2000). Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke, 31(8):1802-11.
75. Van De Werf F (2002). ASSENT-3: implications for future trial design and clinical practice. Eur Heart J, 23(12):911-2.
76. Becker RC, Hochman JS, Cannon CP, Spencer FA, Ball SP, Rizzo MJ, et al (1999). Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol, 33(2):479-87.
77. Angeja BG, Rundle AC, Gurwitz JH, Gore JM, Barron HV (2001). Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction-2. Am J Cardiol, 87(5):627-30.
78. Bueno H, Martínez-Sellés M, Pérez-David E, López-Palop R (2005). Effect of thrombolytic therapy on the risk of cardiac rupture and mortality in older patients with first acute myocardial infarction. Eur Heart J, 26(17):1705-11.
79. Berger AK, Schulman KA, Gersh BJ, Pirzada S, Breall JA, Johnson AE, et al. (1999). Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. JAMA, 282(4):341-8.
80. Maggioni AP, Maseri A, Fresco C, Franzosi MG, Mauri F, Santoro E, et al. (1993). Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell?Infarto Miocardico (GISSI-2). N Engl J Med, 329:1442-1448.
81. Martinez-Selles M, Datino T, Bueno H (2005). Influence of reperfusion therapy on prognosis in patients aged =89 years with acute myocardial infarction. Am J Cardiol, 95:1232-1234.
82. Ryan TJ, Antman EM, Brooks NH, CaliffRM, Hillis LD, Hiratzka LF, et al (1999). 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation, 100(9):1016-30.
83. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. (1997). Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA, 278(23):2093-2098.
84. Berger AK, Schulman KA, Gersh BJ, Pirzada S, Breall JA, Johnson AE, et al. (1999). Primary coronary angioplasty vs thrombolytics for the management of acute myocardial infarction in elderly patients. JAMA, 282:341-348.
85. Ribeiro EE, Silva LA, Carneiro R, D'Oliveira LG, Gasquez A, Amino JG, et al. (1993). Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol, 22(2):376-380.
86. Grinfeld L, Berrocal D, Bellardi J, et al. Fibrinolytics versus primary angioplasty in acute myocardial infarction [abstract]. J Am Coll Cardiol 1996;27(Suppl):A222.
87. Zijlstra F, Beukema WP, Van't Hof AW, Liem A, Reiffers S, Hoorntje JC, et al. (1997). Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. JACC,29:958-1012
88. Ribichini F, Steffenino G, Dellavalle A, et al. Primary angioplasty versus thrombolysis in inferior acute myocardial infarction with anterior ST depressionCa single-center randomized study [abstract]. J Am Coll Cardiol 1996;27:A221.
89. E García, J Elízaga, J Soriano. (1997). Primary angioplasty versus thrombolysis with t-PA in the anterior myocardial infarction [abstract], J Am Coll Cardiol, 29:A-389
90. De Boer MJ, Ottervanger JP, Van't Hof AW, Hoorntje JC, Suryapranata H, Zijlstra F; Zwolle Myocardial Infarction Study Group (2002). Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol, 39(11):1723-8.
91. Grines C. Senior PAMI: a prospective randomized trial of primary angioplasty and thrombolytic therapy in elderly patients with acute myocardial infarction. TCT 2005; October 16-21, 2005; Washington DC.
92. Cequier A, Bueno H, Augé JM, Bardají A, Fernández-Ortiz A, Heras M (2005). Characteristics and mortality following primary percutaneous coronary intervention for acute myocardial infarction in Spain. Results from the TRIANA 1 (TRatamiento del Infarto Agudo de miocardio eN Ancianos) Registry. Rev Esp Cardiol, 58(4):341-50.
93. Bardají A, Bueno H, Fernández-Ortiz A, Cequier A, Augé JM, Heras M (2005). Type of treatment and short-term outcome in elderly patients with acute myocardial infarction admitted to hospitals with a primary coronary angioplasty facility. The TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) Registry) Rev Esp Cardiol, 58(4):351-358
94. Danzi GB, Centola M, Pomidossi GA, Consonni D, De Matteis S, Stabile A, et al (2010). Usefulness of primary angioplasty in nonagenarians with acute myocardial infarction. Am J Cardiol, 106(6):770-773
95. Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ; PCAT Collaborators; percutaneous transluminal coronary angioplasty (2003). Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J, 145: 47-57.
96. Boersma E; The Primary Coronary Angioplasty vs. Thrombolysis Group (2006). Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J, 27:779-788.
97. Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermann M, et al; PRAGUE? Study Group Investigators (2003). Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J, 24:94-104.
98. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, et al; Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) Investigators (2003). Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation, 108:2851-2856.
99. Schomig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, et al.; Beyond 12 Hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators (2005). Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA, 293:2865-2872.
100. Canadian Cardiovascular Society; American Academy of Family Physicians; American College of Cardiology; American Heart Association, Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. (2008). 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 51(2):210-47.
101. Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, et al. (2005). Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med, 353:2758-68.
102. Alp NJ, Gershlick AH, Carver A, Stevens SE, Wilcox R (2008). Rescue angioplasty for failed thrombolysis in older patients: insights from the REACT trial. Int J Cardiol, 125:254-7.
103. Collet JP, Montalescot G, Le May M, Borentain M, Gershlick A (2006). Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol, 48:1326-35.
104. Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, Foody JM, Krumholz HM, Phillips CO, et al. (2007). Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol, 49:422-30.
105. Di Mario C, Dudek D, Piscione F, Mielecki W, Savonitto S, Murena E, et al. (2008). Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet, 371:559-568.
106. Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et al. (2009). Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med, 360:2705-18.
107. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al; SHOCK Investigators (1999). Early revascularization in acute myocardial infarction complicated by cardiogenic shock: should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med, 26:625-634.
108. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, et al. (2000). Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome: a report from the SHOCK Trial Registry: SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol, 36(suppl A):1063-1070.
109. Dzavik V, Sleeper LA, Cocke TP, Moscucci M, Saucedo J, Hosat S, et al; SHOCK Investigators (2003). Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J, 24:828-837.
110. Dauerman HL, Ryan TJ Jr, Piper WD, Kellett MA, Shubrooks SJ, Robb JF, et al. (2003). Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter decade-long experience. J Invasive Cardiol, 15:380-384.
111. Dauerman HL, Goldberg RJ, Malinski M, Yarzebski J, Lessard D, Gore JM (2001). Outcomes and early revascularization for patients > or =65 years of age with cardiogenic shock. Am J Cardiol, 87:844-848.
112. Curtis JP, Alexander JH, Huang Y, Wallentin L, Verheugt FW, Armstrong PW, et al; ASSENT-2 and ASSENT-3 Investigators (2004). Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). Am J Cardiol, 94:279-283.
113. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, et al; ExTRACT-TIMI 25 Investigators (2006). Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med, 354:1477-1488.
114. Sabatine MS, Cannon CP, Gibson CM, Lopez Sendon JL, Montalescot G, Theroux P, et al; CLARITY-TIMI 28 Investigators (2005). Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med, 352:1179-1183.
115. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al; OASIS-6 Trial Group (2006). Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 Randomized Trial. JAMA, 295: 1519-1530.
116. Madsen JK, Chevalier B, Darius H, Rutsch W, Wójcik J, Schneider S, et al. (2008). Ischaemic events and bleeding in patients undergoing percutaneous coronary intervention with concomitant bivalirudin treatment. EuroIntervention, 3(5):610-616.
117. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group (2005). Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet, 366:1607-1621.
118. Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, et al. (2006). Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J, 152:627-35.
119. Wiviott SD, Braunwald E, McCabe CH, French PA, Smyth SS, Becker RC (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 357:2001-2015.
120. US Food and Drug Administration (FDA). Cardiovascular and renal drug advisory committee briefing document on prasugrel for ACS. 2009. http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-01-FDA.pdf (accessed 2 November 2010).
121. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 361:1045-57.
122. Horwitz PA, Berlin JA, Sauer WH, Laskey WK, Krone RJ, Kimmel SE; Registry Committee of the Society for Cardiac Angiography Interventions (2003). Bleeding risk of platelet glycoprotein IIb/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry). Am J Cardiol, 91(7):803-806.
123. Brown DL (2003). Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment. Heart, 89(5):535-537.
124. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. (2001). Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med, 344:1895-903.
125. Prasad A, Stone GW, Aymong E, Zimetbaum PJ, McLaughlin M, Mehran R, et al. (2004). Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. Am Heart J, 147:669-675.
126. Sadeghi HM, Grines CL, Chandra HR, Dixon SR, Boura JA, Dukkipati S, et al. (2003). Percutaneous coronary interventions in octogenarians. glycoprotein IIb/IIIa receptor inhibitors' safety profile. J Am Coll Cardiol, 42:428-432.
127. Dziewierz A, Siudak Z, Rakowski T, Chyrchel M, Mielecki W, Janzon M, et al. (2010). Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in elderly patients transferred with ST-elevation myocardial infarction: data from the EUROTRANSFER registry. Int J Cardiol, 143(2):147-153.
128. Rich MW; PRICE-2 Organizing Committee; PRICE-2 Investigators (2003). Executive summary: Second Pivotal Research in Cardiovascular Syndromes in the Elderly (PRICE-2) symposium. Acute coronary syndromes in the elderly: mechanisms and management. Am J Geriatr Cardiol, 12(5):307-318, 327.
129. Goldberg RJ, Gore JM, Gurwitz JH, Alpert JS, Brady P, Strohsnitter W, et al. (1989). The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J, 117:543-549.
130. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, et al. (2000). Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation, 101(22):2557-2567.
131. Ornato JP, Peberdy MA, Tadler SC, Strobos NC. (2001). Factors associated with the occurrence of cardiac arrest during hospitalization for acute myocardial infarction in the Second National Registry of Myocardial Infarction in the US. Resuscitation, 48:117-123.
132. Burns TR, Klima M, Teasdale TA, Kasper K (1990). Morphometry of the aging heart. Mod Pathol, 3:336-342.
133. Nixon JV, Hallmark H, Page K, Raven PR, Mitchell JH (1985). Ventricular performance in human hearts aged 61 to 73 years. Am J Cardiol, 56:932-937.
134. Mehta RH, Rathore SS, Radford MJ, Wang Y, Wang Y, Krumholz HM (2001). Acute myocardial infarction in the elderly: differences by age. J Am Coll Cardiol, 38:736-741.
135. Thompson CR, Buller CE, Sleeper LA, Antonelli TA, Webb JG, Jaber WA, et al. (2000). Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry: SHould we use emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol, 36(suppl A):1104-1109.
136. Menon V, Webb JG, Hillis LD, Sleeper LA, Abboud R, Dzavik V, et al. (2000). Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry: SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol, 36(suppl A):1110-1116.
137. Waller BF, Rothbaum DA, Pinkerton CA, Cowley MJ, Linnemeier TJ, Orr C, et al. (1987). Status of the myocardium and infarct-related coronary artery in 19 necropsy patients with acute recanalization using pharmacologic (streptokinase, r-tissue plasminogen activator), mechanical (percutaneous transluminal coronary angioplasty) or combined types of reperfusion therapy. J Am Coll Cardiol, 9:785-801.
138. Lenderink T, Hernández AV, Boersma E, Martínez-Sellés M, Juárez M, Sánchez PL, et al. (2010). Prediction of 30-day mortality in older patients with a first acute myocardial infarction. Cardiology, 115(1):1-9.
139. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. (2000). TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation; 102: 2031-2037.